Shots:

• The US FDA approved Zynrelef (bupivacaine and meloxicam) extended-release solution for postsurgical analgesia in patients with soft tissue or periarticular instillation for 72 hrs after a bunionectomy- open inguinal herniorrhaphy and total knee arthroplasty
• The approval is based on data from the P-III studies assessing Zynrelef vs bupivacaine solution in 1000 patients which demonstrated superiority to bupivacaine solution & sustained postoperative pain relief for up to 72 hrs and decreased the need for opioids
• Zynrelef is the 1^st FDA-approved extended-release dual-acting local anesthetic and is approved in 31 EU countries. The company plans to launch Zynrelef in Jul 2021

  Ref: PRNewswire | Image: BioSpace